Helius Medical Financials

HSDT Stock  USD 0.45  0.02  5.35%   
Based on the analysis of Helius Medical's profitability, liquidity, and operating efficiency, Helius Medical Technologies is not in a good financial situation at this time. It has a very high probability of going through financial hardship in December. At this time, Helius Medical's Total Current Assets are comparatively stable compared to the past year. Other Liabilities is likely to gain to about 8.6 M in 2024, whereas Net Debt is likely to drop (5.4 M) in 2024. Key indicators impacting Helius Medical's financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Debt Equity Ratio0.03640.0191
Way Up
Slightly volatile
Current Ratio2.173.9585
Way Down
Slightly volatile
The financial analysis of Helius Medical is a critical element in measuring its lifeblood. Investors should not minimize Helius Medical's ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.

Net Income

(9.29 Million)

  
Understanding current and past Helius Medical Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Helius Medical's financial statements are interrelated, with each one affecting the others. For example, an increase in Helius Medical's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Helius Medical's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Helius Medical Technologies. Check Helius Medical's Beneish M Score to see the likelihood of Helius Medical's management manipulating its earnings.

Helius Medical Stock Summary

Helius Medical competes with Nuwellis, ReShape Lifesciences, Bone Biologics, SINTX Technologies, and Tivic Health. Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. Its product, Portable Neuromodulation Stimulator , is a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. Helius Medical operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 19 people.
Specialization
Health Care, Health Care Equipment & Services
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
ISINUS42328V6039
CUSIP42328V504 42328V603 42328V801
LocationPennsylvania; U.S.A
Business Address642 Newtown Yardley
SectorHealth Care Equipment & Supplies
IndustryHealth Care
BenchmarkDow Jones Industrial
Websiteheliusmedical.com
Phone215 944 6100
CurrencyUSD - US Dollar

Helius Medical Key Financial Ratios

Helius Medical Key Balance Sheet Accounts

201920202021202220232024 (projected)
Total Assets10.3M6.5M14.1M17.3M7.7M9.9M
Net Tangible Assets4.0M3.9M10.2M8.0M9.2M9.7M
Net Debt(4.8M)(3.2M)(11.0M)(14.4M)(5.1M)(5.4M)
Retained Earnings(104.8M)(118.9M)(137.0M)(151.1M)(160.0M)(152.0M)
Accounts Payable1.7M747K1.1M627K531K504.5K
Cash5.5M3.3M11.0M14.5M5.2M7.6M
Other Current Assets610K735K862K1.2M1.0M777.2K
Total Liab4.5M2.7M2.8M9.1M5.3M7.1M
Total Current Assets7.2M4.7M12.6M16.7M7.4M9.1M
Short Term Debt172K118K6K108K90K85.5K
Common Stock26K31K1K4K28K950.0
Other Current Liab1.5M1.3M1.2M1.2M1.0M994.7K
Net Receivables574K230K251K343K637K401.2K
Capital Surpluse6.6M105.4M111.5M123.9M142.5M149.6M
Net Invested Capital5.8M3.9M11.3M8.2M2.4M2.2M
Net Working Capital3.4M2.3M9.9M14.7M5.6M5.8M
Inventory598K389K476K589K457K531.9K

Helius Medical Key Income Statement Accounts

The reason investors look at the income statement is to determine what Helius Medical's earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
201920202021202220232024 (projected)
Interest Expense14.2M256K10K834K257K244.2K
Operating Income(24.0M)(14.4M)(18.1M)(14.8M)(12.4M)(13.0M)
Ebit(38.1M)(14.4M)(18.2M)(14.8M)(12.3M)(12.9M)
Research Development8.1M4.6M6.0M4.3M2.9M2.8M
Ebitda(37.9M)(13.9M)(17.8M)(14.5M)(12.1M)(12.7M)
Income Before Tax(9.8M)(14.1M)(18.1M)(14.1M)(8.9M)(9.3M)
Net Income4.3M(13.9M)(18.1M)(12.6M)(8.9M)(9.3M)
Income Tax Expense(14.1M)(193K)(10K)(1.5M)(5.9K)(6.2K)
Total Revenue1.5M661K522K787K644K458.8K
Gross Profit650K273K224K324K61K58.0K
Cost Of Revenue846K388K298K463K583K612.2K

Helius Medical Key Cash Accounts

201920202021202220232024 (projected)
Change In Cash(20.1M)(2.1M)7.7M3.5M(9.4M)(8.9M)
Free Cash Flow(21.4M)(11.8M)(13.4M)(14.3M)(10.4M)(11.0M)
Other Non Cash Items(13.8M)(56K)82K(1.4M)(3.0M)(3.2M)
Capital Expenditures353K70K56K17K29K27.6K
Net Income(9.8M)(14.1M)(18.1M)(14.1M)(8.9M)(9.3M)
End Period Cash Flow5.5M3.3M11.0M14.5M5.2M7.0M
Investments(769K)(9K)(56K)(11K)(24K)(25.2K)
Depreciation191K482K312K255K162K153.0K
Change To Netincome(9.1M)3.0M4.3M813K731.7K695.1K
Change To Inventory(206K)4K(87K)(111K)137K143.9K

Helius Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Helius Medical's current stock value. Our valuation model uses many indicators to compare Helius Medical value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Helius Medical competition to find correlations between indicators driving Helius Medical's intrinsic value. More Info.
Helius Medical Technologies is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Helius Medical's Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Helius Medical by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Helius Medical Techn Systematic Risk

Helius Medical's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Helius Medical volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was three with a total number of output elements of fifty-eight. The Beta measures systematic risk based on how returns on Helius Medical Techn correlated with the market. If Beta is less than 0 Helius Medical generally moves in the opposite direction as compared to the market. If Helius Medical Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Helius Medical Techn is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Helius Medical is generally in the same direction as the market. If Beta > 1 Helius Medical moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Helius Medical Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Helius Medical's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Helius Medical growth as a starting point in their analysis.

Price Earnings To Growth Ratio

0.007636

At this time, Helius Medical's Price Earnings To Growth Ratio is comparatively stable compared to the past year.

Helius Medical November 23, 2024 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Helius Medical help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Helius Medical Technologies. We use our internally-developed statistical techniques to arrive at the intrinsic value of Helius Medical Technologies based on widely used predictive technical indicators. In general, we focus on analyzing Helius Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Helius Medical's daily price indicators and compare them against related drivers.

Additional Tools for Helius Stock Analysis

When running Helius Medical's price analysis, check to measure Helius Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Helius Medical is operating at the current time. Most of Helius Medical's value examination focuses on studying past and present price action to predict the probability of Helius Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Helius Medical's price. Additionally, you may evaluate how the addition of Helius Medical to your portfolios can decrease your overall portfolio volatility.